PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy.\', \'International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain; Vall d\'Hebron Institute of Oncology (VHIO), Barcelona, Spain.\', \'Department of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.\', \'Division of Breast Surgery, Department of Surgery, Brigham and Women\'s Hospital, Boston, USA; Breast Oncology Program, Dana-Farber/Brigham and Women\'s Cancer Center, Boston, USA.\', \'UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, USA.\', \'Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0923-7534(21)04457-410.1016/j.annonc.2021.08.2153
?:hasPublicationType
?:journal
  • Annals of oncology : official journal of the European Society for Medical Oncology
is ?:pmid of
?:pmid
?:pmid
  • 34500046
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Therapeutic cancer vaccines revamping: technology advancements and pitfalls.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34500046>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34500046>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all